AbundRX Review
Best for: Shoppers wanting straightforward two-tier compounded GLP-1 pricing with free shipping
AbundRX (Abundant Wellness) is an online medical weight-care platform connecting patients with licensed clinicians for compounded GLP-1 treatment. It offers two pathways with transparent pricing — semaglutide-based care at $179/mo and tirzepatide-based care at $279/mo — after a short online assessment, with fast free shipping. Compounded medications are not FDA-approved (disclosed). It publishes Terms, Privacy, and Refund policies. AbundRX states it is LegitScript Certified but shows no verifiable seal, the pharmacy is not named, and its copy is heavily hedged.
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Included
Lab work
Not disclosed
Coaching
Not disclosed
No insurance needed · Vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
AbundRX is a solid telehealth option with balanced features and pricing.
AbundRX at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $179/mo ('Premium Access' $179/mo, fast free shipping)
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How we scored AbundRX
Each dimension is scored algorithmically from AbundRX’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
6.9/10At $179/mo, AbundRX runs about 6% above the $169 median for GLP-1 providers.
Effectiveness25%
8.2/10AbundRX offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
7.5/10Online intake and platform experience — consult included in the price; 8 platform features disclosed.
Trust & Safety15%
7.4/10Core details confirmed by our editors; no FDA warning letters on file (last checked 2026-06-26).
Accessibility10%
6.2/10AbundRX's exact state footprint isn't published — confirm coverage in your state before signing up.
Support10%
6.0/10AbundRX provides standard clinician follow-up; no extended coaching or community program is disclosed.
How we verified this AbundRX review
Last checked 2026-06-26- Confirmed current pricing across 2 dose/plan tiers
- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
GLP-1 medications AbundRX offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
Pricing
'Premium Access' $179/mo, fast free shipping
$279/mo, fast free shipping
Ready to get started?
Plans and promotions change often — check AbundRX's current pricing and active discounts before you decide.
What we like
- Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
- Fast, free shipping and a simple few-minute online health assessment
- Provider-guided care connecting patients with licensed US clinicians
- Publishes Terms, Privacy, and Refund policies
Watch-outs
- Claims LegitScript certification in text but displays no verifiable seal or listing
- Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- Compounding pharmacy not named; no HIPAA notice found; state availability not published
- Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
Is AbundRX worth it? Our verdict
AbundRX positions itself around one thing: Shoppers wanting straightforward two-tier compounded GLP-1 pricing with free shipping. It runs $179/month.
How much AbundRX actually costs
- Compounded semaglutide — $179/month
- Compounded tirzepatide — $279/month
That's roughly in line with the ~$169/month median across the GLP-1 providers we track.
Medications: what AbundRX prescribes
AbundRX prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the two molecules with the strongest published weight-loss trial outcomes. These are dispensed as compounded formulations from a licensed pharmacy, which is how the price stays below brand-name pens. Compounded drugs aren't FDA-approved as finished products — the standard trade-off across the compounded-GLP-1 market.
Who AbundRX is best for — and who should skip it
A good fit if you…
- want a straightforward telehealth GLP-1 program.
Look elsewhere if you…
- specifically want an FDA-approved brand-name pen.
- need to bill insurance — like most of this market, it's cash-pay.
Trust, safety, and medical oversight
We found no FDA warning letters on file for the provider. As with any compounded program, the most important step you can take is confirming which licensed pharmacy fills your prescription and what's in the formulation — we explain how in our scoring methodology.
Bottom line
AbundRX is a reasonable telehealth GLP-1 option; weigh its pricing and coverage against the alternatives below before deciding.
Ready to start with AbundRX?
Starting at $179/month. See current pricing and start your free consultation.
Alternatives to AbundRX
Enhance MD
Best for: lab-monitored compounded GLP-1 with mandatory video visit
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this AbundRX review:
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Ready to start with AbundRX?
Starting at $179/month. See current pricing and start your free consultation.